Roche takes on pricey rivals as FDA approves SMA drug
pharmaphorum
AUGUST 10, 2020
While this is not cheap by anybody’s reckoning, Roche hopes that the less intimidating price tag, plus the patient-friendly oral administration method will give it a competitive edge. Roche leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics.
59 
Let's personalize your content